Pharmazz Inc. Announces Two Presentations on Sovateltide as a Treatment for Acute Ischemic Stroke at the 14th World Stroke Congress
WILLOWBROOK, Ill., Oct. 26, 2022 (GLOBE NEWSWIRE) — Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused…
News
Hepion Pharmaceuticals Announces Publication of Phase 2a ‘AMBITION’ Clinical Trial Results
– Study met safety, tolerability, and pharmacokinetics primary endpoints – – Reductions in ALT, ProC3,…
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
Topline data, including safety and viral load reduction results from all three cohorts anticipated in…
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
BDTX-1535 is an irreversible MasterKey inhibitor of multiple EGFR alterations that utilize similar activated oncogenic…
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
Goal of evaluating combination of novel viral immunotherapies with aim to potentiate CAR-T cell therapies…
Cytek to Participate in the 31st Annual Credit Suisse Healthcare Conference
FREMONT, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”)…
Ascendis Pharma A/S Announces Third Quarter 2022 Financial Results and Business Update Conference Call on November 2
COPENHAGEN, Denmark, Oct. 26, 2022 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) announced today…
Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned
Media Release SYDNEY, AUSTRALIA, Oct. 26, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ:…
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced…
Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage…
Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance
BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted…
BioStem Promotes Michael Fortunato, CPA to Chief Financial Officer
POMPANO BEACH, FLORIDA., Oct. 26, 2022 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (“BioStem” or the…
InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week
VANCOUVER, British Columbia, Oct. 26, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the…
Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma
– First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent…
Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays
Poster for presentation at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics enhances…
Dante Genomics creates separate drug discovery and development company Genomic Biopharma Inc.
– Genomic Biopharma Inc. to present abstracts on two drug candidate programs at the 2022…
Plus Therapeutics Announces Selection of “Rhenium (186Re) Obisbemeda” as International Non-Proprietary Name for 186RNL
AUSTIN, Texas, Oct. 26, 2022 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…
Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., Oct. 26, 2022 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT),…
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma
Study provides additional support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical…
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
Initial Phase 1 data of FHD-609 show degradation of BRD9 in on-treatment metastatic tumor synovial…